Manuela Schmidinger
Overview
Explore the profile of Manuela Schmidinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
5322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Albiges L, Gross-Goupil M, Barthelemy P, Bamias A, Bedke J, Bex A, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39924391
Background And Objective: Management of metastatic renal cell carcinoma (mRCC) remains complex despite clinical guidelines. The aim of this Delphi study was to achieve consensus among RCC experts on the...
2.
Huebner-Resch I, Schmidinger M
Curr Opin Urol
. 2024 Oct;
35(1):28-34.
PMID: 39434633
Purpose Of Review: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for metastatic renal cell carcinoma (mRCC), significantly improving overall survival and achieving durable responses. This review is timely...
3.
Yanagisawa T, Kawada T, Bekku K, Laukhtina E, Rajwa P, von Deimling M, et al.
BJU Int
. 2024 Apr;
134(3):323-336.
PMID: 38659099
Objective: To compare the differential efficacy of first-line immune checkpoint inhibitor (ICI)-based combined therapies among patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of...
4.
Yanagisawa T, Mori K, Matsukawa A, Kawada T, Katayama S, Bekku K, et al.
Cancer Immunol Immunother
. 2024 Jan;
73(2):38.
PMID: 38289361
Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC). However, no head-to-head phase-3 randomized controlled trials (RCTs) have compared the efficacy of...
5.
Motzer R, Porta C, Eto M, Powles T, Grunwald V, Hutson T, et al.
J Clin Oncol
. 2024 Jan;
42(11):1222-1228.
PMID: 38227898
JCO We present the final prespecified overall survival (OS) analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). With an additional follow-up...
6.
Bekku K, Schmidinger M, Katayama S, Kawada T, Yanagisawa T, Iwata T, et al.
Anticancer Res
. 2023 Dec;
44(1):379-386.
PMID: 38160006
Background/aim: Patients with advanced renal cell carcinoma (aRCC) treated with immune-oncology (IO) drugs may need to discontinue the treatment when severe immune-related adverse events (irAE) occur; however, the impact of...
7.
Majdoub M, Yanagisawa T, Quhal F, Laukhtina E, von Deimling M, Kawada T, et al.
Int J Cancer
. 2023 Nov;
154(7):1309-1323.
PMID: 38009868
Renal cell carcinoma (RCC) represents 2% of all diagnosed malignancies worldwide, with disease recurrence affecting 20% to 40% of patients. Existing prognostic recurrence models based on clinicopathological features continue to...
8.
Bruchbacher A, Franke J, Alimohammadi A, Laukhtina E, Fajkovic H, Schmidinger M
Clin Genitourin Cancer
. 2023 Nov;
22(2):98-108.
PMID: 37926597
Background: The multikinase-inhibitor Cabozantinib is a widely used treatment strategy in metastatic renal cell carcinoma (mRCC), either in combination with the programmed cell death protein-1 (PD-1) inhibitor nivolumab or as...
9.
Grimm M, Oya M, Choueiri T, Motzer R, Schmidinger M, Quinn D, et al.
Eur Urol
. 2023 Oct;
85(1):8-12.
PMID: 37852850
Data on the effects of prior cytoreductive nephrectomy (CN) in patients with renal cell carcinoma (RCC) with synchronous metastases (M1 disease) before immune checkpoint inhibitor (ICI) treatment are limited. In...
10.
Grimm M, Esteban E, Barthelemy P, Schmidinger M, Busch J, Valderrama B, et al.
Lancet Oncol
. 2023 Oct;
24(11):1252-1265.
PMID: 37844597
Background: Nivolumab plus ipilimumab is approved as first-line regimen for intermediate-risk or poor-risk metastatic renal cell carcinoma, and nivolumab monotherapy as second-line therapy for all risk groups. We aimed to...